Últimas noticias sobre Gelteq (NASDAQ:GELS) Bolsa

Gelteq

Gelteq Ltd is a clinical and science-based company that is focused on developing and commercializing white-label gel-based delivery solutions to preserve the simplicity, accessibility and efficacy of oral delivery without the impediments traditionally associated with other oral delivery methods, with prescription drugs, nutraceuticals, pet care, and other products. It is engaged in the development and testing of a gel-based delivery system for humans and pets. Its principal products are edible gels.

Gelteq Ltd

GelStat Corp

WIIM

FUBO

FuboTV shares are trading higher after the company announced it will merge with Disney's Hulu business in which Disney will own 70% of the company.

FuboTV shares are trading higher after the company announced it entered into a definitive agreement for Disney to combine its Hulu with Fubo to form a virtual MVPD company.

Transaction Details and Litigation Settlement
In conjunction with the Transaction, Fubo has settled all litigation with Disney and ESPN related to Venu Sports, the previously announced sports streaming platform planned by ESPN, FOX and Warner Bros. Discovery. Fubo has also settled all litigation with FOX and Warner Bros. Discovery.
In connection therewith, at signing of the Transaction, Disney, FOX and Warner Bros. Discovery will make an aggregate cash payment to Fubo of $220 million.
In addition,Disney has committed to provide a $145 million term loan to Fubo in 2026 as part of the Transaction.
Additionally, a termination fee of $130 million will be payable to Fubo under certain circumstances, including if the Transaction fails to close due to the failure to obtain requisite regulatory approvals on the terms and conditions set forth in the definitive agreement.
 &nbsp;

News

Legal

Fubo Settles Litigation With Disney, ESPN, FOX, And Warner Bros. Discovery, Receives $220M Payment; Disney Commits $145M Term Loan For 2026; $130M Termination Fee To Be Paid If Transaction Does Not Close

A recent patient-led case series highlights the potential benefits of extended courses of Pfizer Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Paxlovid (nirmatrelvir / ritonavir) for individuals with Long COVID.
The study documents mixed outcomes among 13 participants, with some reporting meaningful symptom relief and others seeing little to no benefit. The findings underscore the need for more robust clinical research to evaluate the drug's efficacy in managing persistent symptoms of the condition.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38114768/pfizers-paxlovid-demonstrates-safety-but-raises-questions-on-efficacy-in-low-risk-covid-19-patien" rel="noreferrer noopener">Pfizer's Paxlovid Demonstrates Safety But Raises Questions on Efficacy in Low-Risk Covid-19 Patients-NEJM Study</a>
The <a target="_blank" href="https://www.nature.com/articles/s43856-024-00668-8" rel="noreferrer noopener">study</a> involved patients aged 25 to 55 who were infected with SARS-CoV-2 between March 2020 and December 2022 and experienced symptoms such as fatigue, brain fog, muscle pain, irregular heart rate, and post-exertional malaise.
Participants took Paxlovid courses ranging from 7.5 to 30 days, often in combination with other medications or supplements, complicating the assessment of the drug's isolated effects.
While some participants experienced sustained improvement, others noted temporary relief or no change.
Two patients who took extended Paxlovid courses during acute reinfections reported eventual recovery to their pre-reinfection baseline. Another participant discontinued the treatment early due to severe stomach pain, highlighting the need to consider potential side effects.
The study acknowledges its limitations, including small, non-representative sample size and reliance on self-reported data, which may introduce recall or fatigue bias.
However, its participatory approach sheds light on lived experiences that traditional medical records may overlook.
Extended antiviral courses have precedent in other conditions like HIV and hepatitis C, suggesting a basis for further exploration in Long COVID.
Researchers are encouraged to investigate potential treatment pathways, including optimal course lengths and symptom recurrence post-treatment. Larger clinical <a target="_blank" href="https://clinicaltrials.ucsf.edu/trial/NCT05595369" rel="noreferrer noopener">trials</a> are underway to systematically evaluate these factors.
Currently, no FDA-approved treatments specifically target Long COVID. If clinical trials validate Paxlovid's benefits, regulatory pathways like expanded access or fast-track designation could help make the drug available to patients.
Last year, the FDA updated the emergency use <a target="_blank" href="https://www.benzinga.com/general/biotech/24/01/36829826/pfizers-covid-19-treatment-paxlovid-will-no-longer-be-available-for-emergency-use-after-this-date" rel="noreferrer noopener">authorization for&nbsp;Paxlovid</a>.
Price Action: PFE stock is up 0.49% at $26.72 during the premarket session at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42811734/novo-nordisk-pushes-fda-to-exclude-compounding-for-its-early-generation-diabetes-drug" target="_blank" rel="noreferrer noopener">Novo Nordisk Pushes FDA To Exclude Compounding For Its Early-Generation Diabetes Drug</a></li>
</ul>
Photo via Company

Biotech

Large Cap

Health Care

General

Pfizer Antiviral Paxlovid's Extended Use Shows Mixed Results for Long COVID Relief: Study

Outset Medical shares are trading higher after the company announced $169 million in private placement financing. Also, the company reported unaudited Q4 and FY24 revenue results.

Lazydays Holdings, Inc. ("Lazydays" or the "Company") (NasdaqCM: GORV) announced that Jeff Needles has been appointed Chief Financial Officer ("CFO"), effective January 6, 2025. Mr. Needles, the former CFO of Warbird Marine Holdings, LLC, will oversee the Company's financial operations including finance, accounting, treasury, SEC reporting, and financial planning and analysis. Mr. Needles will report to Ron Fleming, Interim CEO of Lazydays.

Management

GORV

Lazydays Appoints Jeff Needles As CFO, Effective January 6, 2025

GDTC

CytoMed Therapeutics shares are trading higher after the company announced it entered into a business and research collaboration agreement with Mumbai-based SunAct Cancer Institute.

<ul>
<li>Brenmiller to drive energy transformation for industrial customers, with a commitment to creating long-term value for shareholders</li>
<li>Brenmiller operates a state-of-the-art TES gigafactory, with capacity to produce up to 4 GWh of bGen&#x2122; systems valued at up to $200 million</li>
<li>Brenmiller is currently developing 7 projects around the world and advancing its $440 million commercial pipeline, aiming to convert it into commercial opportunities for potentially 12 industries across 13 different countries</li>
</ul>
Brenmiller Energy Ltd. ("Brenmiller," "Brenmiller Energy" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNRG#NASDAQ">BNRG</a>), a leading global provider of thermal energy storage ("TES") solutions for industrial and utility customers, is proud to provide shareholders with a comprehensive overview for its end of 2024 activity. Chairman and Chief Executive Officer, Avi Brenmiller, reflects on the Company's achievements during 2024 and outlines the Company's exciting path forward, including insights into strategic initiatives, technological advancements, and how its unwavering commitment to sustainability and innovation can make 2025 a transformative year.

Guidance

BNRG

Brenmiller Energy Chairman And CEO Unveils 2024 Milestone Overview, Highlights TES Gigafactory Capable Of Producing 4 GWh Of Systems Worth $200M; Progresses $440M Worldwide Commercial Pipeline With Joint Ventures And Strategic Partnerships. Noteworthy Projects Include $12-Year HaaS In Hungary And $3.55M Low-Carbon Heat Initiative In Israel

Fubo And Disney's Hulu Businesses To Combine; Disney To Own 70% Of Fubo

Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) shares climbed 2.58% in pre-market trading on Monday, as per <a href="https://pro.benzinga.com">Benzinga Pro</a>. This surge is driven by investor anticipation surrounding CEO Jensen Huang&#8216;s keynote at the CES trade show in Las Vegas.
What Happened: Huang&#8217;s presentation is expected to spotlight the eagerly awaited Blackwell chip. Despite robust demand, the chip has encountered supply chain issues due to manufacturing challenges. Investors are eager for any updates that might revitalize interest in Nvidia&#8217;s stock, which has stagnated since November, Bloomberg<a href="https://www.bloomberg.com/news/articles/2025-01-06/nvidia-investors-look-to-huang-ces-speech-to-spark-next-breakout"> reported</a> on Monday.
Portfolio manager Matt Cioppa from Franklin Templeton Equity Group commented, "The expectation is that Blackwell demand remains very strong." 
This sentiment previously boosted Nvidia&#8217;s stock, with Huang describing demand as &#8220;insane&#8221; in October.
Despite a downturn in December, Nvidia&#8217;s shares have surged 171% in 2024, significantly aiding the S&amp;P 500 Index&#8217;s overall growth. However, the stock faced a setback after a disappointing earnings report in November, resulting in a dip in market value.
As the tech earnings season looms, Nvidia&#8217;s valuation remains a concern. Analysts from&nbsp;Morgan Stanley&nbsp;and&nbsp;Mizuho Securities&nbsp;are closely monitoring Huang&#8217;s keynote, viewing it as a crucial moment for investor sentiment and the company&#8217;s market trajectory.
Why It Matters: Nvidia&#8217;s recent rise is not just about the CES keynote. The company&#8217;s collaboration with Cerence Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNC#NASDAQ">CRNC</a>) to <a href="https://www.benzinga.com/trading-ideas/movers/25/01/42794609/nvidia-shares-are-on-the-rise-today-whats-going-on-2">enhance automotive AI </a>has also played a significant role. This partnership, which integrates Nvidia&#8217;s AI Enterprise software and DRIVE AGX Orin hardware, has bolstered Nvidia&#8217;s market position, driving widespread adoption of its AI chips.
Moreover, Nvidia&#8217;s presence at CES 2025 is significant. The company is expected to unveil its latest RTX 50-series products, potentially setting the stage for a strong start to 2025. Nvidia has historically used CES to showcase upcoming innovations, and this year&#8217;s event could further solidify its standing as a top-performing S&amp;P 500 stock, following a stellar 2024 performance.
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Image via Shutterstock

Pre-Market Outlook

CRNC

NVDA

Nvidia Stock Surges In Monday Pre-Market Ahead Of Jensen Huang's CES Keynote

Getty Images Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GETY#NYSE">GETY</a>) is reportedly exploring a potential merger with rival Shutterstock Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSTK#NYSE">SSTK</a>). The deliberations, disclosed by unnamed sources, reveal that Getty is considering how to structure the deal, though no final decision has been made.
Per a Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2025-01-03/getty-images-explores-merger-with-rival-shutterstock?srnd=phx-latest" rel="noreferrer noopener">report</a> on Saturday, the proposed merger could unite two of the largest providers of licensed visual content in the U.S., underscoring the growing demand for photos, videos, and media in the digital era.
However, Bloomberg notes that such a deal would likely face antitrust scrutiny, regardless of the incoming Trump administration&#8217;s perceived openness to corporate mergers.
Industry observers caution that President-elect Donald Trump&#8217;s antitrust picks—Gail Slater and Andrew Ferguson—are not expected to relax enforcement policies significantly.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/downgrades/24/12/42561153/getty-images-ai-uncertainty-fx-headwinds-premium-valuation-spark-downgrade" rel="noreferrer noopener">Getty Images&#8217; AI Uncertainty, FX Headwinds, Premium Valuation Spark Downgrade</a>
The visual content sector is experiencing transformative changes, with artificial intelligence reshaping content creation and smartphone cameras reducing the traditional value of stock photography.
Mark Getty, a director at Getty Investments, holds about 43% of the company&#8217;s outstanding shares. Other significant investors include Koch Inc. and Neuberger Berman.
In June 2024, Getty Images faced challenges stemming from a U.S. Securities and Exchange Commission investigation into fraudulent stock manipulation by Robert Scott Murray and his firm, Trillium Capital.
The SEC accused Murray of orchestrating a pump-and-dump scheme in 2023 by issuing a false buyout offer for Getty at $10 per share—double the company&#8217;s <a target="_blank" href="https://www.benzinga.com/news/24/06/39124109/getty-images-takeover-bid-was-old-fashioned-pump-and-dump-scheme-finds-sec-massachusetts-man-pleads" rel="noreferrer noopener">closing price at the time</a>.
The SEC alleged that Murray never intended to acquire Getty and liquidated his holdings immediately after the announcement. The court filings described the scheme as &#8220;false and misleading,&#8221; asserting that Murray&#8217;s actions were a calculated attempt to profit from inflated stock prices.
Price Action: At last check on Monday, GETY stock was up 3.77% at $2.48 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42810114/openai-ceo-sam-altman-reveals-company-struggling-with-chatgpt-pro-losses" target="_blank" rel="noreferrer noopener">OpenAI CEO Sam Altman Says Company Losing Money On ChatGPT Pro Plan</a></li>
</ul>
Photo via Shutterstock

Rumors

Tech

GETY

SSTK

Getty Images Weighs Major Merger With Shutterstock That Could Potentially Reshape Visual Content Market

FPAY

FlexShopper shares are trading higher after the company announced record December 2024 results in several key performing metrics.

President-elect Donald Trump's transition team is reworking his universal tariff proposal, signaling potential upheaval in global trade as markets brace for his inauguration on Jan. 20.
According to an <a href="https://www.washingtonpost.com/business/2025/01/06/trump-tariff-economy-trade/">exclusive report</a> by The Washington Post published Monday, the new approach focuses on specific sectors deemed critical to U.S. economic and national security, marking a watered-down version of his 2024 campaign pledge for blanket duties on all imports.
While the plan's final structure remains undecided, early discussions suggest tariffs could target industries such as defense materials, medical supplies and energy production.
If enacted, these tariffs could still significantly disrupt global trade, elevate consumer prices and potentially produce wide-ranging impacts on the U.S. dollar.
<h3 class="wp-block-heading">Trump&#8217;s Tariff Playbook: Targeted But Aggressive</h3>
Instead of implementing a sweeping tax on all imports, discussions among Trump aides suggest that tariffs could be limited to specific sectors. Industries under consideration reportedly include:
<ul>
<li>Defense materials: steel, aluminum, copper</li>
<li>Medical supplies: syringes, vials, pharmaceutical components</li>
<li>Energy production: batteries, rare earth minerals, solar panels</li>
</ul>
The plan appears designed to avoid widespread consumer price shocks that would accompany a blanket tariff on all imports. Still, the policy is being framed as an aggressive move to incentivize domestic manufacturing, a central goal of Trump's trade agenda.
A member of Trump's team described the approach to The Washington Post as a more politically viable way to kick off the administration&#8217;s trade agenda.
"The sector-based universal tariff is a little bit easier for everybody to stomach out the gate," the source said. "And it would still give CEOs a massive incentive to start making their products here."
While the revised strategy may appear more focused, it is no less ambitious. 
Trump's advisers view these measures as a cornerstone of their efforts to bring manufacturing jobs back to U.S. soil. 
Yet, the economic fallout could be significant. Liberal and conservative critics argue that the plan could still raise costs for domestic producers reliant on imported components, driving up prices for consumers and businesses alike.
<h3 class="wp-block-heading">Will Tariffs Hit In Trump's First 48 Hours?</h3>
Markets are closely watching how quickly Trump will move to implement his tariff strategy once inaugurated. CFTC-regulated Kalshi markets estimate a 49% chance that global tariffs will be announced within the first 48 hours of his presidency, by January 23.
Kalshi data also breaks down the likelihood of tariffs targeting specific trade partners. China leads the list at 45%, followed by Canada at 32%, Brazil at 29% and Mexico at 25%.
China is no stranger to Trump's tariff agenda. During his first term, Trump imposed duties on more than $360 billion worth of Chinese goods, citing trade imbalances and intellectual property concerns. 
Trump's new focus on critical sectors may still escalate tensions with America's largest trade partner.
<h3 class="wp-block-heading">Goldman Sachs Sees Tariffs Boosting The Dollar</h3>
Goldman Sachs analysts suggest new tariffs could strengthen the U.S. dollar throughout 2025.
"We expect the Dollar to be ‘stronger for longer' in 2025. Tariff risks and divergent growth prospects will eventually allow the Dollar to strengthen," Kamakshya Trivedi, forex strategist at Goldman said in a recent note.
Trivedi indicated that tariffs directly influence exchange rates by altering the cost of international production.
Historically, Goldman's data shows the U.S. dollar index – as tracked by the  Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>) – has appreciated 2.5% for every unexpected $100 billion in U.S. tariff revenue from China, equivalent to a 20 percentage point tariff increase.
The analyst highlighted that foreign exchange markets often struggle to fully price in tariff risks ahead of time due to uncertainty over policy implementation and potential retaliation. 
Read now: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42809614/us-stocks-to-open-higher-in-yet-another-truncated-week-nvidia-robotic-stocks-in-focus-ahead-of-ces-2025">US Stocks To Open Higher In Yet Another Truncated Week: Nvidia, Robotic Stocks In Focus Ahead Of CES 2025</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Asia

Government

Regulations

Currency ETFs

Econ #s

Economics

Analyst Ratings

ETFs

PowerShares DB US Dollar Index Bullish Fund

Trump's Universal Tariff Plans Take Shape, Analysts Expect 'Stronger For Longer' Greenback

APLD

Applied Digital Appoints Laura Laltrello As COO

Exelixis's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NYSE">EXEL</a>) short percent of float has fallen 12.44% since its last report. The company recently reported that it has 7.33 million shares sold short, which is 3.45% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.58 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Exelixis Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736171121_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Exelixis has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Exelixis's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Exelixis's peer group average for short interest as a percentage of float is 5.03%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

EXEL

(EXEL) - Analyzing Exelixis's Short Interest

NAYA

NAYA Biosciences shares are trading higher after the company announced the development of NY-500 novel AI-optimized PD X VEGF bifunctional antibody.

Block's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQ#NYSE">SQ</a>) short percent of float has risen 28.66% since its last report. The company recently reported that it has 11.76 million shares sold short, which is 2.11% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.25 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Block Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736171116_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Block has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Block's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Block's peer group average for short interest as a percentage of float is 4.91%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Block?

Cabaletta Bio's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CABA#NYSE">CABA</a>) short percent of float has risen 38.24% since its last report. The company recently reported that it has 6.22 million shares sold short, which is 13.16% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.31 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Cabaletta Bio Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736171111_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Cabaletta Bio has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Cabaletta Bio's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Cabaletta Bio's peer group average for short interest as a percentage of float is 10.04%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

CABA

Looking Into Cabaletta Bio's Recent Short Interest

Financial and Operating Results
Funds From Operations as Adjusted ("FFOA") per diluted share are expected to be $0.63 for the fourth quarter 2024 and $2.48 for the full-year 2024, each of which are in-line with the midpoints of the Company's previously provided guidance as described in its third quarter 2024 earnings release published on October 30, 2024.
Preliminary Same-Store ("SS") results for the fourth quarter 2024 and full-year 2024 are summarized below and are better than the midpoints of previously provided guidance.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">SS Growth / (Decline)</td>
<td colspan="1" rowspan="1">
Year-Over-Year:
4Q 2024 vs. 4Q 2023
</td>
<td colspan="1" rowspan="1">
Full-Year:
2024 vs. 2023
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenue</td>
<td colspan="1" rowspan="1">2.5%</td>
<td colspan="1" rowspan="1">2.3%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Expense</td>
<td colspan="1" rowspan="1">3.4%</td>
<td colspan="1" rowspan="1">4.3%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net Operating Income ("NOI")</td>
<td colspan="1" rowspan="1">2.1%</td>
<td colspan="1" rowspan="1">1.5%</td>
</tr>
</tbody>
</table>
</figure><figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">SS Metric</td>
<td colspan="1" rowspan="1">3Q 2024, as reported</td>
<td colspan="1" rowspan="1">4Q 2024, preliminary</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Weighted Average Physical Occupancy</td>
<td colspan="1" rowspan="1">96.3%</td>
<td colspan="1" rowspan="1">96.8%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Effective Blended Lease Rate Growth</td>
<td colspan="1" rowspan="1">1.8%</td>
<td colspan="1" rowspan="1">(0.6)%</td>
</tr>
</tbody>
</table>
</figure>

Earnings

UDR Announces Q4 2024 Preliminary Results, FFOA At $0.63/Share, FY24 At $2.48/Share; SS NOI Growth At 2.1% In Q4, 1.5% For Full-Year; Revenue Increased By 2.5% YoY In Q4; Weighted Average Physical Occupancy Rose To 96.8%

As the most powerful investors in the world are loading up on <a href="https://www.benzinga.com/topic/energy">energy </a>investments following President-elect Donald Trump&#8217;s victory, this investor highlights a profitable and lower-risk oil and gas play that is &#8220;set to outperform all the rest.&#8221;
What Happened: Warren Buffett holds <a href="https://www.benzinga.com/content/42715498/buffett-takes-the-bait-berkshire-buys-more-oxy-in-december">$13.15 billion worth</a> of Occidental Petroleum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>) as of the third quarter of this fiscal year. According to 13F filings, Carl Icahn owns <a href="https://www.benzinga.com/insights/news/25/01/42755511/positive-signal-carl-icahn-shows-faith-buying-339k-in-cvr-partners-stock">$1.53 billion worth</a> of CVR Energy Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CV#NYSE">CV</a>) as of Q3. Meanwhile, billionaire Ken Griffin boosted his holdings in certain <a href="https://www.benzinga.com/markets/asia/22/11/29831732/ken-griffins-hedge-fund-increased-its-stake-by-over-150-in-these-2-dividend-paying-energy-stocks">oil stocks by 150%</a> in 2023.
However, Marc Lichtenfeld, the chief income strategist at the Oxford Club, on Monday revealed a little-known oil strategy that first caught the attention of Buffett's partner, Charlie Munger, in 1962. He explains, &#8220;It has nothing to do with oil futures, ETFs, or stocks. Yet the returns can be MUCH bigger.&#8221;
Lichtenfeld describes oil and gas royalties as a &#8220;backdoor way&#8221; to earn recurring payments from oil fields without the usual costs of exploration, labor, or transportation. &#8220;Instead, you simply collect incredible royalty streams for owning a very valuable asset… the oil or gas field. It's the ultimate passive income investment,&#8221; he says.
Before his passing, Munger <a href="https://www.benzinga.com/personal-finance/24/05/38619559/charlie-munger-and-a-friend-each-made-70-000-per-year-from-a-1-000-investment-60-years-ago-rakin">earned $70,000 annually</a> from an investment of just $1,000 made more than six decades ago. 
See Also: <a href="https://www.benzinga.com/markets/equities/24/11/42383725/trump-administrations-deregulation-efforts-to-lift-energy-oil-and-gas-sectors-ai-frenzy-to-aid-faang-stocks-and-nvidia-says-fintech-insider">Trump&#8217;s Deregulation Efforts To Benefit Energy, Oil And Gas Sectors, While AI Frenzy Will Boost FAANG Stocks And Nvidia, Says Fintech Insider</a>
Why It Matters: Highly regulated industries are likely to benefit under Trump&#8217;s administration due to his proposed deregulation efforts. This includes the creation of the Department of Government Efficiency (DOGE), led by Elon Musk and Vivek Ramaswamy, aimed at cutting the government&#8217;s wasteful spending.
Lichtenfeld highlights that oil and gas royalties offer lower risk than traditional energy stocks. While conventional oil companies face operational challenges and heavy debt, royalties provide a more stable investment.
&#8220;It's a perfect investment during times of high inflation, like right now. In Texas, they call oil royalties &#8216;mailbox money,&#8217; because you walk out, open up the mailbox, and the check is there. It's as easy as it gets,&#8221; he says.
Lichtenfeld also underscores the investment potential of Permian Basin royalties, noting that other U.S. basins are nearing the end of their productive life, while the Permian is at peak production.
&#8220;Unlike with Occidental, you're not investing in a high-capital company that needs to drill, extract, transport, or store any product. You simply collect royalties from this superstar basin. It's a win-win,&#8221; he adds.
See Also: <a href="https://www.benzinga.com/24/11/42131911/donald-trump-appointed-doge-to-have-marginal-impact-saving-50-100-billion-says-analyst-as-elon-musk-aims-to-target-500-billion-plus-in-federal-expenditures" target="_blank" rel="noreferrer noopener">Donald Trump's DOGE Initiative To Have ‘Marginal Impact' Says Analyst As Elon Musk Aims To Target Over $500B In Federal Expenditures</a>
What Are Experts Saying: According to Mario Georgiou, the executive director and head of investments at InCred Global Wealth, "Deregulation supporting oil production and geopolitical risks could sustain elevated oil prices and relative valuations are attractive."
"Fundamentally, (energy) companies are shareholder friendly with 8-12% shareholder yields, have strong balance sheets with low net debt to EBITDA ratios and high free cash flow yields of 6.50% and above," he adds.
According to JPMorgan, oil prices could reach a "stratospheric" $380 a barrel.
As per Morgan Stanley, the energy sector faces a divided future. Trump's deregulation could benefit traditional energy, but the outlook for oil is uncertain due to potential oversupply and weak global demand, especially from China. In contrast, natural gas may see growth from strong European demand and increased domestic use for electrification and AI-powered data centers.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42158682/donald-trumps-win-positive-for-financials-energy-sector-as-pro-growth-effects-will-outweigh-inflationary-pressures-says-analyst">Donald Trump&#8217;s Win Positive For Financials, Energy Sector As &#8216;Pro-Growth Effects Will Outweigh Inflationary Pressures,&#8217; Says Analyst</a></li>
</ul>
Image Via Shutterstock

Equities

Market Summary

Markets

As Warren Buffett And Other Billionaires Load Up On Energy Stocks, This Analyst Highlights Charlie Munger's 1962 Oil Investment Which Can 'Outperform All The Rest'

Benchmark acted as sole book running manager for the offering. Published first on TheFly – the ultimate source for real-time, market-moving breakin...

Gelteq 1.3M share IPO priced at $4.00

Polyrizon and Gelteq made their public debut on Tuesday in a quiet Halloween week for the IPO market. LATEST IPOS AND DIRECT LISTINGS: Polyrizon (P...

Opening Day: Polyrizon, Gelteq debut in quiet IPO week

Gelteq (GELS) announced that it has expanded its operations in the United States with the appointment of Adam Bendell as President of U.S. Operatio...

Gelteq appoints Bendell as President of U.S. Operations

Heritage Distilling, Ming Shing and Dynamix made their public debut as the IPO market cools off ahead of Thanksgiving week in the U.S. LATEST IPOS ...

Opening Day: Heritage Distilling, Dynamix open for trading

Heritage Distilling, Ming Shing, and Dynamix all made a public debut as the IPO market has cooled off ahead of Thanksgiving week in the U.S.

Heritage Distilling, Dynamix Open For Trading

Gelteq (GELS) announced that in November, 400,000 units of its gel solution are entering into production. These units will fulfill orders made for ...

Gelteq announces 400,000 units enter production in November

Gelteq (GELS) announces its largest U.S. customer, Healthy Extracts, has increased its initial purchase order of Gelteq collagen and Mynus sugar bl...

Gelteq announces largest U.S. customer increases initial order by 50%

Gelteq's largest U.S. customer increases initial order by 50%

Gelteq (GELS) Limited announces that the U.S. Food and Drug Administration, FDA, has approved its suitability petition for a new animal drug under ...

Gelteq receives FDA approval of its suitability petition for new animal drug

Gelteq (GELS) announced the appointment of Dr. Paul Wynne as its Chief Scientific Officer. Wynne will oversee the product and formulation strategie...

Gelteq appoints Paul Wynne as CSO

ADBE

CAMP

CASK

CBLL

CLIK

DYNX

GELS

HYEX

PLRZ

SKYQ

STFS

IPOs

Press Releases

Gelteq Limited Closes US$5.2 Million Initial Public Offering

Gelteq Expands Operations in United States with Appointment of Adam Bendell as President of U.S. Operations to Scale Domestic Business

Gelteq Announces 400,000 Units Enter into Production in November 2024

Gelteq Announces Largest U.S. Customer Increases Initial Order by 50% to Meet Growing Market Demand

Gelteq to Participate in the Benchmark Company 13th Annual Discovery Investor Conference

Gelteq Receives FDA Approval of its Suitability Petition for New Animal Drug

Gelteq Appoints Dr. Paul Wynne as Chief Scientific Officer to Propel Innovative Ingestible Gel Technology

Comments

Gelteq

Noticias

Últimas noticias sobre Gelteq (NASDAQ:GELS) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL